Search results
Kansas Attorney General Kris Kobach sues Pfizer over marketing of COVID-19 vaccine
The Kansas City Star· 10 hours agoKansas Attorney General Kris Kobach is suing the pharmaceutical company Pfizer, alleging it deceptively marketed its COVID-19 vaccine. The lawsuit, filed in state court in ...
US FDA approves Merck's pneumococcal vaccine for adults
Reuters· 7 hours ago, opens new tab said on Monday the U.S. Food and Drug Administration has approved its...
Will Pfizer Stock Rebound To Its 2021 Highs Of $60?
Forbes· 24 hours agoPfizer stock (NYSE: PFE) currently trades at $28 per share, 55% below its peak level of $61 seen in December 2021. PFE stock was trading at $52 in early June 2022, just before ...
Pfizer, Flagship to focus on obesity drugs under $100M collaboration - Boston Business Journal
The Business Journals· 5 days agoAlmost a year after Cambridge’s Flagship Pioneering and Pfizer Inc. announced a partnership to...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 4 days agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...
Is this the Time to Initiate a Pfizer (PFE) Position?
Insider Monkey via Yahoo Finance· 7 days agoDiamond Hill Capital, an investment management company, released its “Select Strategy” first-quarter...
Pfizer's Duchenne gene therapy fails in late-stage study
Reuters via Yahoo News· 5 days agoThe therapy also did not show a significant difference compared to placebo in secondary goals of the...
Flagship taps startup to hunt for obesity drugs that might interest Pfizer
BioPharma Dive via Yahoo Finance· 6 days agoThe venture firm will work with ProFound Therapeutics to “rapidly surface” protein drug candidates...
Kansas Attorney General sues Pfizer for misleading covid claims
KOAM· 12 hours ago(KANSAS) -- Kansas Attorney General Kris Kobach is suing Pfizer for misleading claims made related to the COVID vaccine.
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks via Yahoo Finance· 5 days agoPfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory...